How To Read Fibroscan Results: Complete Clinical Interpretation Guide

Understanding your FibroScan (vibration-controlled transient elastography) report requires assessing two main quantitative outputs: the Controlled Attenuation Parameter (CAP) measured in decibels per meter (dB/m) for hepatic steatosis, and the Liver Stiffness Measurement (LSM) expressed in kilopascals (kPa) for fibrosis. Test validity must be confirmed first by verifying at least 10 valid measurements, an Interquartile Range to Median ratio (IQR/M) of 30% or less, and a success rate of at least 60%. Cross-referencing valid kPa and CAP scores against disease-specific cutoffs yields precise staging from S0–S3 for fat accumulation and F0–F4 for liver scarring.

Key Metrics and Report Prerequisites

Interpreting transient elastography results requires evaluating technical performance parameters prior to examining clinical scores. FibroScan devices utilize an ultrasound transducer mounted on a mechanical actuator to send a low-frequency shear wave (50 Hz) through liver tissue. The propagation velocity of this shear wave directly correlates with tissue stiffness: faster wave propagation indicates harder, more fibrotic tissue. Simultaneously, the attenuation of the ultrasound signal measures fat accumulation.

Before reviewing liver disease scores, verify that the exam meets international quality criteria established by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).

• Essential Report Parameters to Identify:

  
  
  
  • Liver Stiffness Measurement (LSM): Calculated in kilopascals (kPa), reflecting tissue elasticity across a dynamic range of 1.5 kPa to 75.0 kPa.
  • Controlled Attenuation Parameter (CAP): Measured in decibels per meter (dB/m), ranging from 100 dB/m to 400 dB/m.
  • Interquartile Range (IQR): The absolute statistical variability among all valid shear wave acquisitions.
  • IQR/Median Ratio (IQR/M or IQR/med): The total IQR divided by the median LSM value, expressed as a percentage.
  • Valid Measurements Count: The total number of successful shear wave transmissions recorded during the session.
  • Success Rate: The ratio of successful acquisitions to total attempts, expressed as a percentage.
  • Probe Type Used: Medium (M) probe for standard anatomy or Extra-Large (XL) probe for patients with an increased skin-to-liver capsule distance (greater than 25 mm).

• Mandatory Quality Control Standards:

  
  
  
  • Minimum of 10 valid acquired measurements.
  • IQR/M ratio equal to or less than 30% for LSM values exceeding 7.1 kPa (the primary indicator of test reliability).
  • Overall measurement success rate of 60% or higher.
  • Patient adherence to a strict 3-hour minimum fast (npo) prior to testing to eliminate postprandial hyperemic flow artifacts.

• Standard Reading Assessment Benchmarks:

  
  
  
  • Interpretation Time: 5 to 10 minutes for full technical review.
  • Clinical Scope: Non-invasive staging of chronic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD), Chronic Hepatitis B (CHB), Chronic Hepatitis C (CHC), and Alcohol-Related Liver Disease (ALD).

Four-Step Workflow for Interpreting a FibroScan Report

Step 1: Validate Report Quality and Acquisition Accuracy

Begin by locating the quality assurance section of the printout, usually positioned near the top or side of the summary metrics. Never attempt to read fibrosis or steatosis scores without validating measurement reliability first.

1. Locate the total number of valid acquisitions. If the number is below 10, the test is clinically unreliable and should be repeated.
2. Check the IQR/M ratio. For a median stiffness reading above 7.1 kPa, an IQR/M value of 30% or less confirms high measurement precision. An IQR/M between 31% and 39% indicates marginal reliability, while an IQR/M of 40% or greater invalidates the stiffness reading, as variance among shots is too wide to yield a stable median.
3. Confirm probe selection appropriateness. Look for the indicator displaying M Probe or XL Probe. If a patient has a Body Mass Index (BMI) over 30 kg/m² or an operator-measured skin-to-capsule distance greater than 25 mm, the XL probe must be utilized. Using an standard M probe on deep tissue falsely elevates the kPa value due to subcutaneous fat signal attenuation.

Warning: Performing a FibroScan examination within 3 hours of meal consumption increases splanchnic blood flow and hepatic arterial pressure. This postprandial hyperemia can falsely elevate the Liver Stiffness Measurement by 2.0 to 5.0 kPa, potentially misdiagnosing a patient with F1/F2 fibrosis as stage F3 or F4.

Step 2: Decode Liver Stiffness Measurement (LSM) for Fibrosis Staging

Locate the primary LSM Median value, printed prominently in units of kPa. Healthy liver tissue typically registers between 2.5 kPa and 6.0 kPa. As extracellular matrix deposition accelerates due to chronic inflammation, tissue elasticity drops, causing the kPa reading to rise.

0 kPa ── [ Healthy: 2.5–6.0 ] ── [ F0-F1: <7.0 ] ── [ F2: 7.0-8.5 ] ── [ F3: 8.5-12.5 ] ── [ F4: ≥12.5+ ] ── 75 kPa

1. Stiffness values under 6.0 kPa to 7.0 kPa: Indicates normal liver elasticity or minimal scar tissue (Stage F0 to F1).
2. Stiffness values between 7.0 kPa and 8.5 kPa: Suggests significant fibrosis (Stage F2). Scar tissue has expanded beyond the portal triads but has not formed extensive bridging networks.
3. Stiffness values between 8.5 kPa and 12.5 kPa: Represents advanced fibrosis (Stage F3). Bridging fibrosis is present, altering normal hepatic architecture.
4. Stiffness values equal to or exceeding 12.5 kPa to 15.0 kPa (depending on etiology): Indicates hepatic cirrhosis (Stage F4). Liver architecture is predominantly replaced by dense regenerative nodules and collagen bands.

Pro-Tip: While 12.5 kPa is a widely accepted universal threshold for ruling in cirrhosis across general populations, specific underlying etiologies alter these diagnostic cutoffs. For instance, MASLD/NAFLD typically utilizes a 13.0 kPa threshold for F4, whereas Chronic Hepatitis B may establish F4 cirrhosis at 11.0 kPa due to lower baseline parenchymal inflammation patterns.

Step 3: Analyze Controlled Attenuation Parameter (CAP) for Steatosis Grading

Scan the report for the CAP score, expressed in decibels per meter (dB/m). The FibroScan device measures the attenuation rate of the ultrasound signal as it travels through tissue; fat accumulation accelerates signal loss, yielding a higher numerical CAP value.

1. CAP score under 248 dB/m: Represents normal liver fat content, classified as Grade S0 (steatosis present in less than 5% to 10% of hepatocytes).
2. CAP score between 248 dB/m and 267 dB/m: Indicates mild hepatic steatosis, classified as Grade S1 (11% to 33% hepatocyte fat involvement).
3. CAP score between 268 dB/m and 279 dB/m: Represents moderate hepatic steatosis, classified as Grade S2 (34% to 66% hepatocyte fat involvement).
4. CAP score of 280 dB/m or higher: Indicates severe hepatic steatosis, classified as Grade S3 (greater than 66% hepatocyte fat involvement).

Step 4: Adjust Interpretation Based on Underlying Etiology and Confounders

Contextualize the kPa and dB/m numbers against patient-specific clinical data. Transient elastography measures physical tissue resistance, not collagen structure exclusively. Consequently, physiological variables other than fibrosis can artificially increase liver stiffness readings.

1. Evaluate Serum Transaminases (ALT/AST): Check recent liver enzyme panel results. Acute hepatocellular necrosis releases cellular fluid and causes acute swelling, which elevates kPa values independent of underlying scarring. Alanine Aminotransferase (ALT) levels elevated to more than 5 times the upper limit of normal (ULN) invalidate standard kPa cutoff charts.
2. Assess Systemic Congestion: Confirm whether the patient has active right-sided heart failure, severe tricuspid regurgitation, or fluid overload. Passive venous congestion of the liver increases intravascular pressure, driving up kPa scores by as much as 10 to 20 kPa without histological fibrosis.
3. Check Biliary System Metrics: Rule out acute extrahepatic biliary obstruction (e.g., choledocholithiasis). Elevated intrahepatic biliary pressure artificially stiffens the hepatic parenchyma.
4. Identify Active Alcohol Consumption: Recent heavy alcohol consumption induces acute alcoholic hepatitis and intrahepatic swelling, resulting in transiently elevated LSM scores that often drop significantly after 2 to 4 weeks of abstinence.

FibroScan Score Reference Ranges and Disease Staging Matrix

The table below outlines established clinical reference ranges across primary etiologies. Cutoffs are based on consolidated data from international consensus guidelines (EASL, AASLD, APASL).

Diagnostic Pitfalls and Erroneous Result Remedies

Scenario 1: High IQR/M Ratio (> 30%) Rendered Report Invalid

• Root Cause: Rapid operator transducer movement, patient breathing motion during acquisition shots, narrow intercostal spaces restricting acoustic access, or attempting measurements over a focal liver lesion or major hepatic blood vessel.
• Actionable Fix: Re-evaluate the patient in strict supine position with the right arm fully extended above the head to widen intercostal spaces. Instruct the patient to perform shallow breath-holds at end-expiration during image collection. If thorax anatomy is challenging, select a secondary intercostal window located 1 to 2 centimeters anterior or superior to the initial mark.

Scenario 2: Unusually High Stiffness Reading (kPa) with Normal Liver Enzymes and No Risk Factors

• Root Cause: False-positive fibrosis elevated by non-fibrotic conditions. Common causes include unannounced food intake within 3 hours prior to the scan, acute subclinical hepatitis flare, acute biliary colic causing intrahepatic cholestasis, or occult right heart failure causing hepatic congestion.
• Actionable Fix: Verify strict fasting compliance. Order a complete metabolic panel, ALT/AST, total bilirubin, alkaline phosphatase, and a baseline echocardiogram or hepatic vein duplex ultrasound. Postpone re-testing for 4 to 8 weeks after acute inflammatory flares resolve before assigning a definitive fibrosis stage.

Scenario 3: Failed Acquisition or Unreliable Readings in Obese Patients

• Root Cause: Acoustic dampening caused by a thick subcutaneous fat layer when using a standard Medium (M) probe. The M probe focal depth (25 mm to 65 mm below the skin surface) gets trapped within the chest wall fat pad, preventing shear wave propagation into hepatic parenchyma.
• Actionable Fix: Switch immediately to the Extra-Large (XL) probe, which utilizes a lower transducer central frequency (1.82 MHz vs. 3.5 MHz for M probe), a larger vibration amplitude, and a deeper focal region (35 mm to 75 mm below skin level). Ensure the automatic probe selection tool built into the software confirms probe compatibility based on skin-to-capsule distance.

Scenario 4: Significant Discordance Between FibroScan Results and Blood-Based Biomarkers (e.g., FIB-4 or NAFLD Fibrosis Score)

• Root Cause: Biological discordance resulting from systemic variable interference. Blood panels rely on indirect metabolic markers (platelets, AST, ALT, age) which can be skewed by non-hepatic conditions (e.g., idiopathic thrombocytopenia or age over 65), whereas FibroScan measures direct physical stiffness.
• Actionable Fix: Apply a dual-testing algorithmic pathway. When transient elastography and blood panels yield discordant risk categories (e.g., low-risk FIB-4 score coupled with high-risk FibroScan kPa), perform a second-line non-invasive assessment such as Magnetic Resonance Elastography (MRE) or schedule an image-guided percutaneous liver biopsy for definitive histological confirmation.

Frequently Asked Questions

What is a normal FibroScan result for a healthy individual?

A normal FibroScan result for a healthy adult without underlying liver conditions features a Liver Stiffness Measurement (LSM) between 2.5 kPa and 6.0 kPa and a CAP score under 248 dB/m. These values confirm the absence of significant liver scarring (F0-F1) and minimal hepatic fat accumulation (S0).

Can a FibroScan reading falsely suggest cirrhosis?

Yes, transient elastography can produce false-positive cirrhosis results. Factors such as recent food consumption, acute hepatic inflammation with elevated transaminases (ALT > 5x upper limit of normal), right-sided heart failure causing liver congestion, heavy alcohol consumption, or acute bile duct obstruction can artificially elevate kPa readings into the F4 range despite minimal structural scarring.

What is the primary difference between the CAP score and the kPa score?

The CAP score measures the attenuation of ultrasound waves to quantify the amount of fat in the liver (steatosis), expressed in decibels per meter (dB/m). The kPa score measures the propagation speed of mechanical shear waves to determine the elasticity or stiffness of the liver tissue, quantifying structural scar tissue (fibrosis).

Can elevated FibroScan scores decrease over time?

FibroScan scores can improve over time. Successful treatment of underlying causes—such as sustained viral clearance in Hepatitis C, viral suppression in Hepatitis B, weight loss and metabolic control in MASLD, or prolonged abstinence from alcohol—can lower liver fat (CAP) and decrease tissue inflammation and stiffness (kPa).

Why is fasting mandatory for at least 3 hours before a FibroScan?

Fasting is required because eating triggers postprandial hyperemia, an increase in blood flow through the portal vein into the liver during digestion. This temporary increase in intrahepatic blood volume and vascular pressure artificially raises liver stiffness readings by up to several kilopascals, leading to overestimation of fibrosis stage.

Discussing Your FibroScan Results With Your Specialist

Interpreting a FibroScan report requires balancing technical quality metrics alongside a patient's broader clinical profile. If your report shows elevated kPa or CAP values, consult a board-certified hepatologist or gastroenterologist to integrate these non-invasive metrics into a comprehensive management plan.